Persistent pulmonary hypertension of the newborn

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Persistent pulmonary hypertension of the newborn (PPHN) is often secondary to pa- renchymal lung disease (such as meconium aspiration syndrome) or lung hypoplasia (with congenital diaphragmatic hernia) but can also be idiopathic. PPHN is character- ized by elevated pulmonary vascular resistance, resulting in right-to-left shunting of blood and hypoxemia. The diagnosis of PPHN is based on clinical evidence of labile hypoxemia often associated with differential cyanosis and confirmed by echocardiogra- phy. Lung volume recruitment with optimal use of positive end-expiratory pressure or mean airway pressure and/or surfactant is very important in secondary PPHN due to parenchymal lung disease. Other management strategies include optimal oxygenation, avoiding respiratory and metabolic acidosis, blood pressure stabilization, sedation, and pulmonary vasodilator therapy. Failure of these measures leads to consideration of ex- tracorporeal membrane oxygenation, although this rescue therapy is needed less fre- quently with advances in medical management. Randomized clinical trials with long-term follow-up are required to evaluate various therapeutic strategies in PPHN.

Original languageEnglish (US)
Pages (from-to)e680-e694
JournalNeoReviews
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Persistent Fetal Circulation Syndrome
Lung
Lung Diseases
Meconium Aspiration Syndrome
Respiratory Acidosis
Extracorporeal Membrane Oxygenation
Cyanosis
Positive-Pressure Respiration
Acidosis
Vasodilator Agents
Surface-Active Agents
Vascular Resistance
Echocardiography
Therapeutics
Randomized Controlled Trials
Blood Pressure
Pressure

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Persistent pulmonary hypertension of the newborn. / Lakshminrusimha, Satyanarayana; Keszler, Martin.

In: NeoReviews, Vol. 16, No. 12, 01.12.2015, p. e680-e694.

Research output: Contribution to journalArticle

Lakshminrusimha, Satyanarayana ; Keszler, Martin. / Persistent pulmonary hypertension of the newborn. In: NeoReviews. 2015 ; Vol. 16, No. 12. pp. e680-e694.
@article{f68a2bf4fa4644f5a446cf194e9f7b80,
title = "Persistent pulmonary hypertension of the newborn",
abstract = "Persistent pulmonary hypertension of the newborn (PPHN) is often secondary to pa- renchymal lung disease (such as meconium aspiration syndrome) or lung hypoplasia (with congenital diaphragmatic hernia) but can also be idiopathic. PPHN is character- ized by elevated pulmonary vascular resistance, resulting in right-to-left shunting of blood and hypoxemia. The diagnosis of PPHN is based on clinical evidence of labile hypoxemia often associated with differential cyanosis and confirmed by echocardiogra- phy. Lung volume recruitment with optimal use of positive end-expiratory pressure or mean airway pressure and/or surfactant is very important in secondary PPHN due to parenchymal lung disease. Other management strategies include optimal oxygenation, avoiding respiratory and metabolic acidosis, blood pressure stabilization, sedation, and pulmonary vasodilator therapy. Failure of these measures leads to consideration of ex- tracorporeal membrane oxygenation, although this rescue therapy is needed less fre- quently with advances in medical management. Randomized clinical trials with long-term follow-up are required to evaluate various therapeutic strategies in PPHN.",
author = "Satyanarayana Lakshminrusimha and Martin Keszler",
year = "2015",
month = "12",
day = "1",
doi = "10.1542/neo.16-12-e680",
language = "English (US)",
volume = "16",
pages = "e680--e694",
journal = "NeoReviews",
issn = "1526-9906",
publisher = "American Academy of Pediatrics",
number = "12",

}

TY - JOUR

T1 - Persistent pulmonary hypertension of the newborn

AU - Lakshminrusimha, Satyanarayana

AU - Keszler, Martin

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Persistent pulmonary hypertension of the newborn (PPHN) is often secondary to pa- renchymal lung disease (such as meconium aspiration syndrome) or lung hypoplasia (with congenital diaphragmatic hernia) but can also be idiopathic. PPHN is character- ized by elevated pulmonary vascular resistance, resulting in right-to-left shunting of blood and hypoxemia. The diagnosis of PPHN is based on clinical evidence of labile hypoxemia often associated with differential cyanosis and confirmed by echocardiogra- phy. Lung volume recruitment with optimal use of positive end-expiratory pressure or mean airway pressure and/or surfactant is very important in secondary PPHN due to parenchymal lung disease. Other management strategies include optimal oxygenation, avoiding respiratory and metabolic acidosis, blood pressure stabilization, sedation, and pulmonary vasodilator therapy. Failure of these measures leads to consideration of ex- tracorporeal membrane oxygenation, although this rescue therapy is needed less fre- quently with advances in medical management. Randomized clinical trials with long-term follow-up are required to evaluate various therapeutic strategies in PPHN.

AB - Persistent pulmonary hypertension of the newborn (PPHN) is often secondary to pa- renchymal lung disease (such as meconium aspiration syndrome) or lung hypoplasia (with congenital diaphragmatic hernia) but can also be idiopathic. PPHN is character- ized by elevated pulmonary vascular resistance, resulting in right-to-left shunting of blood and hypoxemia. The diagnosis of PPHN is based on clinical evidence of labile hypoxemia often associated with differential cyanosis and confirmed by echocardiogra- phy. Lung volume recruitment with optimal use of positive end-expiratory pressure or mean airway pressure and/or surfactant is very important in secondary PPHN due to parenchymal lung disease. Other management strategies include optimal oxygenation, avoiding respiratory and metabolic acidosis, blood pressure stabilization, sedation, and pulmonary vasodilator therapy. Failure of these measures leads to consideration of ex- tracorporeal membrane oxygenation, although this rescue therapy is needed less fre- quently with advances in medical management. Randomized clinical trials with long-term follow-up are required to evaluate various therapeutic strategies in PPHN.

UR - http://www.scopus.com/inward/record.url?scp=84957686737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957686737&partnerID=8YFLogxK

U2 - 10.1542/neo.16-12-e680

DO - 10.1542/neo.16-12-e680

M3 - Article

AN - SCOPUS:84957686737

VL - 16

SP - e680-e694

JO - NeoReviews

JF - NeoReviews

SN - 1526-9906

IS - 12

ER -